PPARA and non-small cell lung carcinoma: Another ongoing interventional study (ClinicalTrials.gov Identifier: NCT02852083), using a combination of chemicals and comprising 86 participants of all sexes in Phase II, aims to determine the safety and effectiveness of a combination modularized treatment of treosulfan, a PPAR agonist PIO, and clarithromycin in patients with SCC and NSCLC after platin failure.